Product
AI AGENTS
INTELLIGENCE SUITE
API, MCP & INTEGRATION
Solutions
INDUSTRIES
USE CASES
Pricing
Resources
EXPLORE
ENGAGE
SUPPORT & SERVICES
About
Patsnap Eureka Platform
IP Search Agents
IP Drafting Agents
Engineering Agents
Find Solutions with TRIZ
Life Sciences Agents
Materials Agents
SEP Agents
Patsnap Eureka Desktop
BetaAnalytics
IP IntelligenceSynapse
Biopharma IntelligenceBio
Biosequence Search and AnalysisChemical
Chemical Structure Search and AnalysisProfessional Services
Open Platform
Developer Center
Customer Stories
Newsroom
Blog
Global Innovation Report
Glossary
Webinars & Training
User Community
R&D Benchmark Calculator
Trust and Security
PatentBench
NEWLLM
Help center
Careers
Access to over 2,000,000,000 structured data points around patents, science, litigation, and tech sectors
Innovate 75% faster at 25% less cost
Cloud or on-prem for maximum privacy and control
Trusted by more than 18,000 innovators worldwide
To use , click the vertification button in the email we sent to [email protected].
This helps keep your account secure.
You should receive it shortly. Don’t forget to check your spam folder.
Unlock professional features and history
Already have an account? Log In
To start using Patsnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Thoughtfully curated series offering valuable insights for innovation professionals
Article | Report Ifinatamab deruxtecan's DeLLphi-304 Phase III trial is redefining first-line small cell lung cancer treatment. Explore the science, patent landscape, and clinical implications.
Article | Report No verified patent or literature data was found for deterministic latency in industrial Ethernet for real-time robot control. Learn what this means for your research.
Article | Report Ulotaront, ralmitaront, and the TAAR1 agonist pipeline are reshaping schizophrenia and depression drug discovery. See the competitive landscape.
Article | Report Explore the key technical tradeoffs between hydrogen combustion and fuel cell powertrains for aviation — efficiency, weight, emissions, and integration challenges.
Article | Report Roche's trontinemab uses a transferrin receptor brain-shuttle to deliver amyloid-beta antibody at higher brain concentrations with a differentiated ARIA profile. Full Phase II analysis.
Article | Report How do model-based and data-driven fault detection methods compare for industrial rotating machinery? A technical guide for R&D and IP professionals.
Article | Report Oveporexton is the first orexin receptor agonist targeting narcolepsy type 1. Explore its FDA approval trajectory, mechanism, and competitive market dynamics.
Article | Report Key engineering challenges of building reliable humanoid robots for industrial deployment at scale — from actuator reliability to locomotion control and dexterity.
Article | Report Explore the key differences between physics-based and data-driven modeling for industrial process optimization, including hybrid approaches and when to use each.
Article | Report Tirzepatide's SURPASS-CVOT trial examines GLP-1/GIP dual agonist cardiovascular and renal outcomes in type 2 diabetes. Explore the science, IP landscape, and clinical significance.
Article | Report How do open-source and proprietary LLMs differ for enterprise R&D? Compare customisation, cost, compliance, and performance to make smarter AI deployment decisions.
Article | Report Sparsentan targets both ETA and AT1 receptors for FSGS and IgAN treatment. Explore the dual receptor antagonism mechanism, IP landscape, and clinical signals.
Article | Report IMerge Phase 3 trial: imetelstat achieved 39.8% 8-week transfusion independence vs 15% placebo in lower-risk MDS. Full pipeline analysis and biomarker data.
Article | Report Key design considerations for thermal management in next-generation AI server rack deployments — cooling strategies, power density challenges, and engineering frameworks.
Article | Report How olutasidenib differs from ivosidenib in IDH1-mutated relapsed AML, plus emerging combination strategies with venetoclax and azacitidine.